Considerable academic and commercial research efforts are underway in order to identify and utilize genetic biomarkers to aid in the diagnosis and characterization of prostate cancers, to determine their aggressiveness, to ascertain the need for biopsies, and to monitor therapeutic regimens. These have been reviewed in this website’s blog posts dated March 26th, 2012 and more recently, July 16th, 2013. Two such genetic markers found in urine are PCA3 (developed by Gen-Probe and approved by the FDA as PROGENSA PCA3) and TMPRSS2:ERG (from the University of Michigan). A three-way collaboration is underway between these two entities and the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to combine and maximize the accuracy and utility of these tests. These efforts have been described in detail in an article published on September 30th by the Prostate Cancer Foundation (PCF). I suggest reading the entire article. If you feel that these tests may be applicable to your specific prostate cancer condition, definitely discuss them with your urologist, oncologist or medical provider.